You just read:

ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)

News provided by

ViroPharma Incorporated

Sep 13, 2011, 03:00 ET